沃森生物水痘减毒活疫苗临床试验获批

Core Viewpoint - Watson Bio has received approval from the National Medical Products Administration for clinical trials of its varicella live attenuated vaccine, developed in collaboration with its subsidiaries [1] Group 1: Vaccine Development - The varicella live attenuated vaccine is developed using a live attenuated strain of the varicella-zoster virus and is produced through a freeze-drying process [1] - The vaccine aims to stimulate the immune system to produce immunity against the varicella-zoster virus for the prevention of chickenpox [1] Group 2: Market Context - Currently, there are six companies in China that have received marketing approval for their varicella live attenuated vaccines [1]